BNGO logo

Bionano Genomics, Inc. Stock Price

NasdaqCM:BNGO Community·US$18.9m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 41 Fair Values set on narratives written by author

BNGO Share Price Performance

US$1.95
-19.06 (-90.72%)
82.3% undervalued intrinsic discount
US$11.00
Fair Value
US$1.95
-19.06 (-90.72%)
82.3% undervalued intrinsic discount
US$11.00
Fair Value
Price US$1.95
AnalystHighTarget US$11.00
AnalystConsensusTarget US$9.50
AnalystLowTarget US$8.00

BNGO Community Narratives

AnalystHighTarget·
Fair Value US$11 82.0% undervalued intrinsic discount

Precision Medicine And Genomic Tools Will Expand Clinical Adoption

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystConsensusTarget·
Fair Value US$9.5 79.2% undervalued intrinsic discount

Digital Pathology Transition Will Advance Precision Medicine Adoption

0users have liked this narrative
0users have commented on this narrative
28users have followed this narrative
AnalystLowTarget·
Fair Value US$8 75.3% undervalued intrinsic discount

Operating Losses Will Curb Genomics Progress Yet Kindle Modest Recovery

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent BNGO News & Updates

A Piece Of The Puzzle Missing From Bionano Genomics, Inc.'s (NASDAQ:BNGO) 28% Share Price Climb

Sep 14
A Piece Of The Puzzle Missing From Bionano Genomics, Inc.'s (NASDAQ:BNGO) 28% Share Price Climb

Investors Continue Waiting On Sidelines For Bionano Genomics, Inc. (NASDAQ:BNGO)

Jul 30
Investors Continue Waiting On Sidelines For Bionano Genomics, Inc. (NASDAQ:BNGO)

Bionano Genomics, Inc. Key Details

US$27.4m

Revenue

US$26.0m

Cost of Revenue

US$1.4m

Gross Profit

US$75.7m

Other Expenses

-US$74.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-7.68
Gross Margin
5.06%
Net Profit Margin
-271.02%
Debt/Equity Ratio
25.9%

Bionano Genomics, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks
2 Rewards

About BNGO

Founded
2003
Employees
99
CEO
Robert Holmlin
WebsiteView website
bionano.com

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›